Mineralocorticoid receptors in the metabolic syndrome

Trends in Endocrinology and Metabolism

Volumn 20, Issue 9, 2009, Pages 444-451

  Zennaro, Maria Christina ^a,b,c   Caprio, Massimiliano ^d,e   Fève, Bruno ^f,g,h  

^a PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d IRCCS SAN RAFFAELE PISANA   (Italy)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

^f INSERM   (France)

^g UNIVERSITÉ PARIS SACLAY   (France)

^h BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ALDOSTERONE; ANGIOTENSINOGEN; CYTOKINE; EPLERENONE; GLUCOCORTICOID RECEPTOR; GLUCOSE; INSULIN; MINERALOCORTICOID RECEPTOR; REACTIVE OXYGEN METABOLITE; SPIRONOLACTONE;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CELL DIFFERENTIATION; CELL FUNCTION; DISORDERS OF CARBOHYDRATE METABOLISM; ENZYME INACTIVATION; HORMONE SYNTHESIS; HUMAN; INSULIN RESISTANCE; METABOLIC SYNDROME X; MOLECULAR MECHANICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

ALDOSTERONE; ANIMALS; GLUCOCORTICOIDS; HUMANS; METABOLIC SYNDROME X; MINERALOCORTICOIDS; MODELS, BIOLOGICAL; RECEPTORS, MINERALOCORTICOID;

EID: 72149099639     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2009.05.006     Document Type: Review

References (91)

1. Ronconi V., et al. Adipose cell-adrenal interactions: current knowledge and future perspectives. Trends Endocrinol. Metab. 19 (2008) 100-103
2. Caprio M., et al. Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J. 21 (2007) 2185-2194
3. Pearce D., et al. Aldosterone: its receptor, target genes, and actions. Vitam. Horm. 66 (2003) 29-76
4. Viengchareun S., et al. The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology. Nucl. Recept. Signal 5 (2007) e012
5. Verrey F., et al. Pleiotropic action of aldosterone in epithelia mediated by transcription and post-transcription mechanisms. Kidney Int. 57 (2000) 1277-1282
6. Pujo L., et al. Mineralocorticoid receptor mutations are the principal cause of renal type 1 pseudohypoaldosteronism. Hum. Mutat. 28 (2007) 33-40
7. Lifton R.P., et al. Molecular mechanisms of human hypertension. Cell 104 (2001) 545-556
8. Arriza J.L., et al. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 237 (1987) 268-275
9. Funder J.W., et al. The roles of plasma binding and receptor specificity in the mineralocorticoid action of aldosterone. Endocrinology 92 (1973) 994-1004
10. Farman N., and Rafestin-Oblin M.E. Multiple aspects of mineralocorticoid selectivity. Am. J. Physiol. Renal. Physiol. 280 (2001) F181-192
11. Funder J.W. Mineralocorticoid receptors: distribution and activation. Heart Fail Rev 10 (2005) 15-22
12. Cornier M.A., et al. The metabolic syndrome. Endocr. Rev. 29 (2008) 777-822
13. Gustafson B., et al. Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 2276-2283
14. Wilson P.W., and Meigs J.B. Cardiometabolic risk: a Framingham perspective. Int. J. Obes. (Lond.) 32 Suppl 2 (2008) S17-20
15. Feve B. Adipogenesis: cellular and molecular aspects. Best Pract. Res. Clin. Endocrinol. Metab. 19 (2005) 483-499
16. Antuna-Puente B., et al. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab. 34 (2008) 2-11
17. Skurk T., et al. Relationship between adipocyte size and adipokine expression and secretion. J. Clin. Endocrinol. Metab. 92 (2007) 1023-1033
18. Weisberg S.P., et al. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112 (2003) 1796-1808
19. Bastard J.P., et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur. Cytokine Netw. 17 (2006) 4-12
20. MacDougald O.A., and Mandrup S. Adipogenesis: forces that tip the scales. Trends Endocrinol. Metab. 13 (2002) 5-11
21. Hotamisligil G.S. The role of TNFalpha and TNF receptors in obesity and insulin resistance. J. Intern. Med. 245 (1999) 621-625
22. Rossi G.P., et al. Primary aldosteronism: cardiovascular, renal and metabolic implications. Trends Endocrinol. Metab. 19 (2008) 88-90
23. Savoia C., et al. Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension 51 (2008) 432-439
24. Bochud M., et al. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension 48 (2006) 239-245
25. Kidambi S., et al. Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. Hypertension 49 (2007) 704-711
26. Ingelsson E., et al. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study. Circulation 116 (2007) 984-992
27. Vasan R.S., et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N. Engl. J. Med. 351 (2004) 33-41
28. Fallo F., et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J. Clin. Endocrinol. Metab. 91 (2006) 454-459
29. Ranade K., et al. Genetic variation in aldosterone synthase predicts plasma glucose levels. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 13219-13224
30. Connell J.M., and Davies E. The new biology of aldosterone. J. Endocrinol. 186 (2005) 1-20
31. Young M.J., et al. Mineralocorticoid receptor activation and cardiac fibrosis. Clin. Sci. (Lond.) 112 (2007) 467-475
32. Nagase M., et al. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J. Am. Soc. Nephrol. 17 (2006) 3438-3446
33. Nagase M., et al. Salt-induced nephropathy in obese spontaneously hypertensive rats via paradoxical activation of the mineralocorticoid receptor: role of oxidative stress. Hypertension 50 (2007) 877-883
34. Shibata S., et al. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat. Med. 14 (2008) 1370-1376
35. Chrysostomou A., and Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N. Engl. J. Med. 345 (2001) 925-926
36. Pitt B. The role of aldosterone blockade in patients with heart failure. Heart Fail. Rev. 10 (2005) 79-83
37. Plouin P.F., and Jeunemaitre X. Would wider screening for primary aldosteronism give any health benefits? Eur. J. Endocrinol. 151 (2004) 305-308
38. Rossi G.P., et al. Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Circulation 95 (1997) 1471-1478
39. Milliez P., et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J. Am. Coll. Cardiol. 45 (2005) 1243-1248
40. Stowasser M., et al. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J. Clin. Endocrinol. Metab. 90 (2005) 5070-5076
41. Farquharson C.A., and Struthers A.D. Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin. Sci. (Lond.) 103 (2002) 425-431
42. Farquharson C.A., and Struthers A.D. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 101 (2000) 594-597
43. Leopold J.A., et al. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat. Med. 13 (2007) 189-197
44. Caprio M., et al. Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ Res 102 (2008) 1359-1367
45. Garrison R.J., et al. Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev. Med. 16 (1987) 235-251
46. Pausova Z. From big fat cells to high blood pressure: a pathway to obesity-associated hypertension. Curr. Opin. Nephrol. Hypertens. 15 (2006) 173-178
47. Despres J.P., and Lemieux I. Abdominal obesity and metabolic syndrome. Nature 444 (2006) 881-887
48. Cooper R., et al. ACE, angiotensinogen and obesity: a potential pathway leading to hypertension. J. Hum. Hypertens. 11 (1997) 107-111
49. Goodfriend T.L., et al. Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women. Obes. Res. 7 (1999) 355-362
50. Masuzaki H., et al. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J. Clin. Invest. 112 (2003) 83-90
51. Devenport L.D., et al. Continuous infusion of aldosterone: correlates of body weight gain. Pharmacol. Biochem. Behav. 22 (1985) 707-709
52. Hauner H., et al. Promoting effects of glucocorticoids on the differentiation of human adipocyte precursor cells cultured in a chemically defined medium. J. Clin. Invest. 84 (1989) 1663-1670
53. Rondinone C.M., et al. Aldosterone stimulates differentiation of mouse 3T3-L1 cells into adipocytes. Endocrinology 132 (1993) 2421-2426
54. Fu M., et al. A Nuclear Receptor Atlas: 3T3-L1 adipogenesis. Mol. Endocrinol. 19 (2005) 2437-2450
55. Penfornis P., et al. The mineralocorticoid receptor mediates aldosterone-induced differentiation of T37i cells into brown adipocytes. Am. J. Physiol. Endocrinol. Metab. 279 (2000) E386-394
56. Zennaro M.C., et al. Hibernoma development in transgenic mice identifies brown adipose tissue as a novel target of aldosterone action. J. Clin. Invest. 101 (1998) 1254-1260
57. Viengchareun S., et al. Mineralocorticoid and glucocorticoid receptors inhibit UCP expression and function in brown adipocytes. Am. J. Physiol. Endocrinol. Metab. 280 (2001) E640-649
58. Lowell B.B., et al. Development of obesity in transgenic mice after genetic ablation of brown adipose tissue. Nature 366 (1993) 740-742
59. Almind K., et al. Ectopic brown adipose tissue in muscle provides a mechanism for differences in risk of metabolic syndrome in mice. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 2366-2371
60. van Marken Lichtenbelt W.D., et al. Cold-activated brown adipose tissue in healthy men. N. Engl. J. Med. 360 (2009) 1500-1508
61. Virtanen K.A., et al. Functional brown adipose tissue in healthy adults. N. Engl. J. Med. 360 (2009) 1518-1525
62. Cypess A.M., et al. Identification and importance of brown adipose tissue in adult humans. N. Engl. J. Med. 360 (2009) 1509-1517
63. Gregoire F.M., et al. Understanding adipocyte differentiation. Physiol. Rev. 78 (1998) 783-809
64. Masuzaki H., et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 294 (2001) 2166-2170
65. Newell-Price J., et al. Cushing's syndrome. Lancet 367 (2006) 1605-1617
66. Morton N.M., et al. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 53 (2004) 931-938
67. Kershaw E.E., et al. Adipocyte-specific glucocorticoid inactivation protects against diet-induced obesity. Diabetes 54 (2005) 1023-1031
68. Yang X., et al. Nuclear receptor expression links the circadian clock to metabolism. Cell 126 (2006) 801-810
69. Rickard A.J., and Young M.J. Corticosteroid receptors, macrophages and cardiovascular disease. J. Mol. Endocrinol. 42 (2009) 449-459
70. Luther J.M., et al. Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism. Hypertension 48 (2006) 1050-1057
71. Sawathiparnich P., et al. Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans. J. Clin. Endocrinol. Metab. 87 (2002) 448-452
72. Guo C., et al. Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus. Endocrinology 147 (2006) 5363-5373
73. Joffe H.V., et al. Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus. J. Clin. Endocrinol. Metab. 92 (2007) 2552-2558
74. Matsumoto S., et al. The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy. Metabolism 55 (2006) 1645-1652
75. Takebayashi K., et al. Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. J. Clin. Endocrinol. Metab. 91 (2006) 2214-2217
76. Bianchi S., et al. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 70 (2006) 2116-2123
77. Guo C., et al. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation 117 (2008) 2253-2261
78. Lastra G., et al. Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat. Am. J. Physiol. Endocrinol. Metab. 295 (2008) E110-116
79. Liu G., et al. Mineralocorticoid receptor is involved in the regulation of genes responsible for hepatic glucose production. Biochem. Biophys. Res. Commun. 342 (2006) 1291-1296
80. Hitomi H., et al. Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells. Hypertension 50 (2007) 750-755
81. Calle C., et al. Transcriptional inhibition of the human insulin receptor gene by aldosterone. J. Steroid. Biochem. Mol. Biol. 84 (2003) 543-553
82. Bjorntorp P. Do stress reactions cause abdominal obesity and comorbidities?. Obes. Rev. 2 (2001) 73-86
83. DeRijk R.H., et al. A common polymorphism in the mineralocorticoid receptor modulates stress responsiveness. J. Clin. Endocrinol. Metab. 91 (2006) 5083-5089
84. Conn J.W., et al. Clinical Characteristics Of Primary Aldosteronism From An Analysis Of 145 Cases. Am. J. Surg. 107 (1964) 159-172
85. Mosso L.M., et al. A possible association between primary aldosteronism and a lower beta-cell function. J. Hypertens. 25 (2007) 2125-2130
86. Fallo F., et al. Adiponectin and insulin sensitivity in primary aldosteronism. Am. J. Hypertens. 20 (2007) 855-861
87. Matrozova J., et al. Fasting plasma glucose and serum lipids in patients with primary aldosteronism: a controlled cross-sectional study. Hypertension 53 (2009) 605-610
88. Haluzik M., et al. Serum leptin levels in patients with primary hyperaldosteronism before and after treatment: relationships to insulin sensitivity. J. Hum. Hypertens. 16 (2002) 41-45
89. Giacchetti G., et al. Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. J. Hypertens. 25 (2007) 177-186
90. Strauch B., et al. Does the treatment of primary hyperaldosteronism influence glucose tolerance?. Physiol. Res. 52 (2003) 503-506
91. Catena C., et al. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J. Clin. Endocrinol. Metab. 91 (2006) 3457-3463